Roche reports the Prasinezumab aids in early-stage Parkinson's
The main goal of the Phase IIb study wasn't met with statistically significant results, but there is still some good news On Dec. 18, 2024, Roche shared results from a Phase IIb study (PADOVA) where prasinezumab, an investigational monoclonal antibody (mAb), did not meet the study’s primary